- Home
- FAMI vs HSCS Comparison
FAMI vs HSCS Comparison
Compare FAMI & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FAMI
- HSCS
- Stock Information
- Founded
- FAMI 2015
- HSCS 2007
- Country
- FAMI China
- HSCS United States
- Employees
- FAMI N/A
- HSCS N/A
- Industry
- FAMI Packaged Foods
- HSCS Medical Specialities
- Sector
- FAMI Consumer Staples
- HSCS Health Care
- Exchange
- FAMI Nasdaq
- HSCS Nasdaq
- Market Cap
- FAMI 3.1M
- HSCS 2.8M
- IPO Year
- FAMI 2018
- HSCS 2022
- Fundamental
- Price
- FAMI $0.16
- HSCS $3.05
- Analyst Decision
- FAMI
- HSCS Strong Buy
- Analyst Count
- FAMI 0
- HSCS 2
- Target Price
- FAMI N/A
- HSCS $13.50
- AVG Volume (30 Days)
- FAMI 4.4M
- HSCS 18.8K
- Earning Date
- FAMI 03-21-2025
- HSCS 03-25-2025
- Dividend Yield
- FAMI N/A
- HSCS N/A
- EPS Growth
- FAMI N/A
- HSCS N/A
- EPS
- FAMI N/A
- HSCS N/A
- Revenue
- FAMI $64,131,332.00
- HSCS $14,700.00
- Revenue This Year
- FAMI N/A
- HSCS $174.19
- Revenue Next Year
- FAMI N/A
- HSCS $4,100.00
- P/E Ratio
- FAMI N/A
- HSCS N/A
- Revenue Growth
- FAMI N/A
- HSCS 151.28
- 52 Week Low
- FAMI $0.15
- HSCS $2.36
- 52 Week High
- FAMI $0.94
- HSCS $13.50
- Technical
- Relative Strength Index (RSI)
- FAMI 24.69
- HSCS 40.90
- Support Level
- FAMI $0.23
- HSCS $2.72
- Resistance Level
- FAMI $0.29
- HSCS $3.58
- Average True Range (ATR)
- FAMI 0.02
- HSCS 0.35
- MACD
- FAMI -0.01
- HSCS -0.06
- Stochastic Oscillator
- FAMI 9.79
- HSCS 33.92
About FAMI Farmmi Inc.
Farmmi Inc is a supplier of agricultural products. The products of the company are Shiitake Mushroom, Mu Er Mushroom and other edible fungi and other agricultural products. The majority of products are sold in mainland China.
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.